Lanifibranor - Inventiva Pharma

Drug Profile

Lanifibranor - Inventiva Pharma

Alternative Names: IVA-337

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inventiva Pharma
  • Class Antifibrotics; Antihyperglycaemics; Antineoplastics; Hepatoprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Systemic scleroderma
  • Preclinical Bladder cancer; Fibrosis
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 20 Jun 2018 US FDA approves IND application for phase II trial of lanifibranor for Type-2 diabetic patients with Non-alcoholic fatty liver disease
  • 13 Apr 2018 Inventiva plans a phase III trial for Non-alcoholic steatohepatitis and clinical development in Systemic sclerosis
  • 03 Apr 2018 Inventiva files an IND application with the US FDA for Type-2 diabetic patients with Non-alcoholic fatty liver disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top